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1. Introduction 
Monoclonal antibodies (mAbs) represent a significant portion of products in the 
biopharmaceuticals market (Reichert, 2011; Scolnik, 2009). mAbs have been developed to 
treat a variety of indications to address significant unmet medical needs (Waldmann, 2003; 
Reichert & Valge-Archer, 2007; Ziegelbauer et al., 2008), and are generally target-specific 
and well tolerated with a relatively long half-life, contributing to the success of the molecule 
class for drug development (Scolnik, 2009). Of the classes of antibodies, or 
immunoglobulins, IgG1 is the most common immunoglobulin used for pharmaceutical and 
biomedical purposes (Reichert et al., 2005); however, other immunoglobulin types (e.g., 
IgG2, IgG4) and mAb-related products (e.g., Fc-fusion proteins, Fabs, etc.) are also being 
used for therapeutic purposes (Hudson & Souriau, 2003).  
While a successful mAb product can generate upwards of a billion dollars or more in sales 
annually (Reichert, 2009), it takes a significant amount of time and resources to develop a 
new therapeutic mAb; current estimates indicate that it can take about 10-15 years (Dickson 
& Gagnon, 2004; DiMasi et al., 2003) and over $1 billion to bring a new biologic drug to 
market (DiMasi & Grabowski, 2007). Addressing bottlenecks and making improvements in 
the development process is essential to save time and money, expediting the delivery of new 
drugs to the clinic.  
This chapter will briefly cover monoclonal antibody development, production and 
purification, and then focus on antibody characterization, particularly charge-species 
analysis using high performance ion exchange chromatography (IEC). Method development 
strategies, method robustness, validation and automation will be discussed. This chapter 
aims to be a reference text demonstrating the utility of IEC as well as providing strategies 
for developing rugged IEC methods for the characterization of therapeutic mAbs.  
2. Monoclonal antibody development 
Antibodies are physiological blood components that are produced by B lymphocytes, 
intended to bind to and neutralize foreign antigens and pathogens. Antibodies bind to a 
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corresponding antigen in a highly specific manner. Although not covered in this chapter, 
potential mechanisms of action for mAbs have been described (Green et al., 2000). 
Polyclonal antibodies are a combination of immunoglobulin molecules secreted against a 
specific antigen, each identifying a different epitope. In contrast, monoclonal antibodies are 
derived from a single cell line that are all clones of a unique parent cell.  
The first monoclonal antibody product was approved in 1986 and was a murine antibody 
for the prevention of kidney transplant rejection; however, patients frequently developed 
antibodies against the mouse-derived mAbs, which limited their effectiveness (Jones et al., 
2007; Kuus-Reichel et al., 1994; Shawler et al., 1985). Advances in antibody engineering 
yielded techniques for generating chimeric mAbs that contain sequences from both human 
and murine sources (Morrison et al., 1984; Reichmann et al., 1988). Many of the mAbs 
approved for commercialization in the 1990s and early 2000s were chimeric antibodies. 
Chimeric antibody products are superior to murine antibodies, but they still pose a risk of 
immunogenicity to patients from their residual murine components (Carter, 2001). New 
technologies were developed to produce humanized mAbs, which contain approximately 
95% human components and 5% murine components (Carter & Presta, 2000, 2002). In these 
humanized mAbs, the CDRs of a human antibody gene were replaced by those from the 
CDR of a murine mAb gene (Figure 1). The resulting humanized antibody has the same 
antigen binding properties as the original murine antibody but contains minimal murine 
sequences (Co & Queen, 1991).  
 
Fig. 1. Schematic representation of the sequence composition of murine, chimeric, 
humanized, and human antibodies. 
More recently, less immunogenic therapeutic antibody products were developed by creating 
fully human mAbs. Several technologies exist to develop fully human antibodies, each 
falling into one of the two general classes—in vivo approaches using a murine system in 
which the immunoglobulin genes have been replaced by their human counterparts, or in 
vitro approaches such as phage display libraries containing millions of variations of 
antibody sequences coupled with a mechanism to express and screen these antibodies in 
vitro (Lonberg, 2005; McCafferty et al., 1990). Combining in vivo and in vitro discovery and 
molecular engineering technologies allows exquisite control of the antibody sequences and 
properties that was not possible when mAbs were first developed. Because of these 
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advanced antibody engineering technologies, almost all antibody products currently in 
development are humanized or fully human mAbs and their derivatives.  
3. Monoclonal antibody production  
Recombinant monoclonal antibodies are typically produced in mammalian cell lines under 
defined cell culture conditions. Commercial scale production processes vary depending on 
the mAb, but generally, cells are taken from a master cell bank and inoculated into small-
scale bioreactors. The cell culture is transferred to increasingly larger bioreactors until it 
reaches the final commercial scale bioreactor. Currently, final scale reactors have volumes 
ranging from 12,000 L to 24,000 L (Gottschalk, 2009). The cells are cultured in a controlled 
environment for days to weeks, and then the cell culture fluid is harvested by centrifugation 
(Shukla & Kandula, 2008). In mammalian cells, the product monoclonal antibodies are 
secreted from the cells into the supporting fluid medium. Centrifugation separates the cells 
from the fluids and facilitates simpler recovery procedures downstream. 
Commercial mAb production requires considerable preproduction effort to ensure that the cell 
line is stable and can produce commercially appropriate quantities of antibody. In addition, 
the commercial production process must produce a product that meets the quality 
expectations of regulatory authorities. In the past few years, improvements have been made in 
critical areas, such as cell line generation and large-scale cell culture production, to maximize 
specific antibody productivity from a given cell line and improve overall productivity in 
bioreactors. These advances include the use of new expression vectors and transfection 
technology, high-throughput, robust screening technologies to select the highest producing 
clones rapidly and more effectively, improvements in cell culture and optimized bioreactor 
processes (Li et al., 2010; Schlatter et al., 2005). As a result, the production of cell lines 
expressing multigram quantities of antibody per liter of culture medium is now routine. 
The product quality and product heterogeneity of every mAb is highly dependent on its 
manufacturing process (Abu-Absi et al., 2010; Horvath et al., 2010). The ideal manufacturing 
conditions would have optimal production levels of product in conjunction with the desired 
product quality profile. Attributes that are typically deemed critical in selecting stable clones 
and cell culture conditions are the product titer and product heterogeneity, including 
charged species and aggregates. Production titers directly correlate to the costs of the 
process and are desired to be as high as possible with minimal impact to other quality 
attributes of the product (Kelley, 2009). Critical quality attributes of the product, such as the 
level of aggregation, are carefully monitored, as failure to control critical quality attributes 
may pose a safety risk to the patient (Rosenberg, 2006).  
4. Monoclonal antibody purification and formulation  
Once monoclonal antibodies are produced in cells, the mAbs must be recovered and 
purified. Recovery and purification processes vary widely depending on the manufacturing 
process and specific mAb characteristics, but generally, the isolation and purification of 
mAbs involve a centrifugation step to separate the cells from the cell culture fluid 
containing the mAb product, one or more chromatography steps, which can include affinity 
chromatography, cation or anion exchange chromatography, hydrophobic interaction 
chromatography (HIC) and displacement chromatography (Shukla et al., 2007), and 
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filtration or precipitation steps (Gottschalk, 2009). Many of the purification steps are 
designed to remove contaminants and adventitious agents (e.g., bacteria, fungi, viruses, and 
mycoplasma).  
After elution from the final chromatographic purification step, a unit operation is required 
to exchange the components of the chromatography elution buffer with the chosen 
formulation components. The predominant technology that has been used in the industry 
for buffer exchange and concentration is ultrafiltration/diafiltration using tangential-flow 
filtration (Genovesi, 1983; Shiloach, 1988; van Reis, 2001). After this step, the drug substance 
is filtered and typically frozen as bulk for storage until filling occurs to produce the final 
drug product. 
The formulation of the mAb therapeutic is chosen in part to ensure product quality during 
shelf life. Formulations are designed to minimize protein aggregation, decrease viscosity, 
and increase shelf life through preventing degradation (Shire, 2009). High protein 
concentration formulations are being developed to allow for subcutaneous or intramuscular 
delivery of mAb products (Shire et al., 2004). Historically, the most conventional route of 
delivery for protein drugs has been intravenous administration because of poor 
bioavailability by most other routes, greater control during clinical administration, and 
faster pharmaceutical development. Subcutaneous delivery allows for home administration 
and improved patient compliance. However, development of high protein concentration 
formulations involves unique manufacturing challenges compared to low concentration 
formulations, such as higher viscosities and necessary changes to unit operation steps.    
5. Monoclonal antibody characterization and release testing  
Biopharmaceutical manufacturing of monoclonal antibodies produces a heterogeneous 
product of structurally related species. Antibody speciation can occur throughout the 
manufacturing process at various steps, including cell culture, harvest, purification, 
formulation, filling and during shelf life. Full-length monoclonal antibodies are high 
molecular weight proteins (around 150,000 Da), and have highly complex secondary and 
tertiary structures, subject to post-translational modifications. Therefore, product 
characterization and quality control testing are required at critical points throughout clinical 
development and manufacturing to control for these species (Harris et al., 2004). Figure 2 
depicts the structure of a monoclonal antibody compared to a small molecule drug, 
illustrating the increased complexity of a biologic compared to a small molecule therapeutic. 
Antibodies can be characterized by many physicochemical properties including hydrated 
size (Stokes radius), molecular weight, charge, hydrophobicity, electrophoretic mobility, 
isoelectric point (pI), sedimentation velocity, glycosylation, and spectral properties. The 
nature of each species can be related to differences in their primary, secondary, tertiary, or 
quaternary protein structures. In addition, monoclonal antibodies are susceptible to 
chemical or enzymatic modification, particularly at sites that are exposed to the protein-
liquid interface. Product heterogeneity can be caused by a number of modifications, such as 
C-terminal processing of lysine residues (Harris, 1995; Santora et al., 1999; Weitzhandler et 
al., 1998), deamidation (Di Donato et al., 1993; Hsu et al., 1998), glycation (nonenzymatic 
glucose addition) (Quan et al., 2008), amino acid sequence variations (Yang et al., 2010), and 
noncovalent complexes (Santora et al., 2001).  
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Antibody products are characterized by physicochemical, immunochemical, and biological 
methods. Guidance documents have been issued by regulatory agencies and industry 
representatives recommending approaches for protein characterization (International 
Conference on Harmonisation of Technical Requirements for the Registration of 
Pharmaceuticals for Human Use (ICH), 1999; Schnerman et al., 2004). These orthogonal 
assays include potency, identity and purity assays, which evaluate “critical quality 
attributes” such as size and charge heterogeneity. These critical quality attributes are part of 
the overall target product profile, which is based on the desired clinical performance. The 
extent of characterization is linked to the level of risk associated with each phase of drug 
development. For example, while there may not be sufficient time or resources for extensive 
characterization of an antibody during early stage development, it is expected that the 
molecule will be well-characterized before the Biologic License Application (BLA) is 
submitted to the regulatory agencies.  
 
Fig. 2. Comparison of the structures of a mAb (Herceptin) and a small molecule therapeutic 
(Tarceva).  
Many of the recommended protein characterization assays are based on liquid 
chromatography methods, such as ion exchange chromatography (IEC) for charge 
heterogeneity analysis, size exclusion chromatography (SEC) for size heterogeneity, and 
reversed-phase high performance liquid chromatography (RP-HPLC) for peptide mapping 
(Chirino & Mire-Sluis, 2004). The remainder of this chapter will primarily focus on ion 
exchange chromatography methods for analyzing charge heterogeneity for characterization 
and support of formulation and process development, as well as for lot release testing of 
drug substance and drug product (Schnerman et al., 2004).  
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5.1 Analyzing mAb charge heterogeneity using IEC 
As mentioned previously, monoclonal antibodies are large proteins that are quite complex. 
While the light chain and heavy chain sequences of a particular mAb may be known, a 
number of modifications can introduce heterogeneity in the product. Thus, it is important to 
develop appropriate analytical methods to resolve the minor forms of the product. 
Analytical biochemists routinely use IEC for resolving charge variants of the protein. The 
scientist must then utilize orthogonal analytical methods to characterize the separated peaks 
of the ion exchange chromatogram. The characterization of a mAb is particularly important 
if the modifications occur in the complementarity-determining regions (CDR), as 
modifications in the CDR can affect the binding activity and potency of the mAb.  
A strategy for the assignment of peaks from a weak cation exchange (WCX) mAb 
separation using a salt gradient has been published (Harris et al., 2001).  Seven forms of a 
therapeutic recombinant antibody were resolved by cation-exchange chromatography. 
The peak fractions were collected, and structural differences were assigned by peptide 
mapping, which involves digesting the mAb with an enzyme and injecting the digest onto 
a reverse-phase column coupled to a mass spectrometer, and by hydrophobic interaction 
chromatography (HIC) after papain digestion. The peaks in this particular case were 
attributed to deamidation, isomerization, and succinimide intermediates. Other 
orthogonal analytical methods were used to characterize the IEC peaks; one of these 
methods—potency testing—determined that one minor peak demonstrated much lower 
potency than the main peak. 
In another study, a recombinant humanized monoclonal IgG1 antibody with different 
states of glycosylation on the conserved asparagine residue in the CH2 domain was 
analyzed by cation exchange chromatography (Gaza-Bulseco et al., 2008). Two major 
peaks were observed and were further characterized by enzymatic digestion and mass 
spectrometry. It was found that this recombinant monoclonal antibody contained three 
glycosylation states—zero, one or two glycosylated heavy chains. The peak that eluted 
earlier on the cation exchange column contained antibodies with two glycosylated heavy 
chains containing fucosylated biantennary complex oligosaccharides with zero, one or 
two terminal galactose residues. The peak that eluted later from the column contained 
antibodies with zero, one or two glycosylated heavy chains. The oligosaccharide on the 
antibodies that eluted in the later peak was composed of only two GlcNAc residues. These 
results indicate that conformational changes, caused by different types of neutral 
oligosaccharides as well as the absence of certain oligosaccharides, can be differentiated 
by cation exchange column chromatography. 
5.2 Lot release testing of mAbs 
Once the mAb is purified and formulated, the resulting drug substance must be tested prior 
to lot release. A set of tests and acceptance criteria are established based on mAb 
characterization and regulatory requirements in order to ensure product quality (Food & 
Drug Administration (FDA), 1999). These tests typically include appearance, identity, 
purity, protein concentration, potency of the molecule, microbial limits or bioburden, and 
bacterial endotoxins (Table 1). IEC is one of the most frequently used lot release methods for 
purity for mAbs (Schnerman et al., 2004). Once these tests are performed and the results 
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meet the established acceptance criteria, a Certificate of Analysis (COA) is generated and the 
lot is released for use. Finally, adequate stability studies should be performed on the mAb 
drug substance (e.g. frozen bulk for storage) and drug product (e.g. final vial) according to 
regulatory guidelines (Food & Drug Administration (FDA), 2003).  
Attribute Test Name 
Appearance Color, Opalescence and Clarity 
Identity 
Peptide Mapping by RP-HPLC (Reverse-Phase HPLC), or 
MALDI (Matrix-Assisted Laser Deionization) Mass Spectrometry, or 
UV Spectroscopy (2nd Derivative) 
Purity 
Limulus Amebocyte Lysate (Endotoxin) 
Size Exclusion Chromatography (SEC) 
CE-SDS (Capillary Electrophoresis-Sodium Dodecyl Sulfate) 
IEC (Ion Exchange Chromatography) or icIEF (Imaged Capillary 
Isoeletric Focusing) 
Glycosylation Profile 
Peptide Mapping by RP-HPLC 
Potency Potency (ELISA/Cell-Based Assay) 
Strength UV Spectroscopy 
General Tests 
Osmolality 
pH 
Surfactant Concentration (e.g. Polysorbate 20) 
Table 1. Commonly used tests found on a Certificate of Analysis for lot release; a selected 
subset is used for stability testing of mAbs. 
6. Mechanism of ion exchange chromatography of mAbs 
Ion exchange chromatography (IEC) has been a platform for monoclonal antibody 
purification and characterization for many years. For the analysis of charged species of 
proteins, IEC is a popular method due to the fact that it preserves the native conformation 
and maintains bioactivity of the protein, is relatively easy of use, is supported by the 
maturity of the equipment and consumables market, and has widespread use in the 
biopharmaceutical industry (Rea et al., 2010).  
Charge-based methods are an integral component of characterization studies and quality 
control strategies because they are sensitive to many types of modifications. Charge 
profiling of intact antibodies can resolve species related to protein conformation, size, 
sequence species, glycosylation and post-translational modifications (Gaza-Bulseco et al., 
2008; Harris et al., 2001; He et al., 2010). Although IEC can be used to track specific species, it 
is common to group all species not associated with the main peak and report them as either 
acidic or basic species (Figure 3). In addition, fractions collected from an IEC run can often 
be directly injected onto orthogonal columns for further analysis, such as reverse-phase and 
size exclusion chromatography columns, or submitted for potency testing. 
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IEC separates proteins based on differences in the surface charge of the molecules, with 
separation being dictated by the protein interaction with the stationary phase. The two main 
categories of ion exchange chromatography are cation exchange (CEX) and anion exchange 
(AEX). Cation exchange chromatography retains biomolecules by the interaction of the 
negatively-charged resin with histidine (pK ~ 6.5), lysine (pK ~ 10) and arginine (pK ~ 12) in 
the protein. Anion exchange chromatography primarily retains biomolecules by the 
interaction of the positively-charged resin with aspartic or glutamic acid side chains, which 
have pKa of ~4.4. In addition to the amino acid residues, cation exchange columns can also 
separate deamidated, glycated and other charged variants. Anion exchange columns have also 
been useful for separating phosphorylated and hydroxyl modified amino acids. When the pH 
equals the pI value of the protein, the net charge on the molecule is zero. However, significant 
retention can occur for proteins even when the pH of the mobile phase is equal to the pI of the 
molecule; despite an overall net charge of zero, only a portion of the mAb molecule will interact 
with the stationary phase, and there will be a net charge on that portion of the molecule because 
of an uneven distribution of charged groups throughout the molecule (Vlasak & Ionescu, 2008). 
Thus, it is possible to separate proteins having very similar charge (Figure 4), or even structural 
isomers with identical pI values, by ion exchange chromatography. 
 
Fig. 3. Typical cation exchange chromatogram for analytical characterization of a mAb. 
Integration is shown, and main peak, acidic and basic regions are denoted. 
There are two ways to elute the protein from the IEC column: 1) increasing salt 
concentration with time or 2) by varying the mobile phase pH value as a function of time. 
Increasing the salt concentration elutes the protein by increasing the ionic strength of the 
mobile phase, thus affecting the charge interaction of the mAb and the stationary phase. A 
pH gradient elutes the protein by changing the charge on the molecule, thus affecting the 
binding of the molecule to the stationary phase. While conventional salt gradient cation 
exchange chromatography is regarded as the gold standard for charge sensitive antibody 
analysis (Vlasak & Ionescu, 2008), method parameters such as column type, mobile phase 
pH, and salt concentration gradient often need to be optimized for each individual antibody. 
A recent publication described a multi-product pH gradient IEC method for the separation 
of mAb charge species for a variety of mAbs using a single method (Farnan & Moreno, 
2009). The following sections will discuss both salt-gradient and pH-gradient based elution 
methods, and the combination of the two modalities (hybrid methods). 
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Fig. 4. Separation of mAbs differing by only one charge, a single amino acid change to 
primary structure. The elution buffer (0.5 M NaCl in 20 mM Tris, pH 7.3) was increased 
linearly on a ProPac WCX-10 column (4 x 250 mm), which was held at 50 ºC and had a flow 
rate of 1 mL min-1.  
7. Developing a salt-based IEC method 
Salt-based IEC separations are developed by choosing a cation or anion exchange column 
and varying the buffer system, mobile phase pH value, and ionic strength gradient of the 
elution buffer. Figure 5 shows a typical development workflow for salt-based IEC and pH-
based IEC development, and can serve as a guide for initial IEC method development. The 
following sections will cover in more detail the outputs to consider when screening various 
parameters during development. More general considerations regarding HPLC method 
development can be found in various texts (Kastner, 2000; Snyder et al., 1997).  
               
 
Fig. 5. Sequential salt-gradient IEC and pH-gradient IEC method development and 
optimization work flow. 
Salt Gradient IEC pH Gradient IEC 
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7.1 Column selection, buffers and operating parameters for salt gradient IEC 
Column selection is perhaps the most subjective part of the optimization process; picking 
between the different vendor offerings and functionalities can be difficult. Prior experience, 
data in the literature or unpublished results within the organization are often the best 
starting points.  
Analytical ion exchange chromatography of proteins is typically carried out using mobile 
phases that are relatively neutral in pH values, 5.5 to 8.5 This general practice is 
recommended because at pH extremes, the protein is more likely to degrade. The selection 
of whether to use anion or cation exchange chromatography is also driven by the isoelectric 
point of the protein (pI) and the species to be resolved, e.g., phosphorylated species, C-
terminal lysine variants, etc.  
If the pI value of the mAb is greater than 8, a CEX column is evaluated at pH 6-7 initially. 
CEX primarily retains mAbs by the interaction of acid groups on the CEX resin with lysine, 
arginine and histidine side chains on the mAb. Since mAbs are positively charged at a 
mobile phase pH below their pI, the mAb species would likely be retained and resolved on a 
CEX column under the recommended mobile phase pH range. 
If the pI value of the mAb is less than 6, an AEX column is evaluated at a pH above 6 
initially. AEX primarily retains biomolecules by the interaction of amine groups on the ion 
exchange resin with aspartic or glutamic acid side chains. Since mAbs are negatively 
charged at a mobile phase pH above their pI, the mAb species would likely be retained and 
resolved on an AEX column. 
For intermediate pI values of 6-8, both CEX and AEX are evaluated because of the 
possibility that the portion of the mAb that interacts with the stationary phase, typically the 
side chains that are exposed to the mobile phase, has a different charge than the pI would 
suggest, e.g., the surface charge of the mAb is positive despite the entire mAb having an 
overall negative charge. Ultimately, the species of interest that are to be resolved determine 
whether CEX or AEX is chosen for molecules with intermediate pI’s; the separation mode 
that better separates the species of interest is usually the one that is chosen for mAb analysis. 
Figure 6 shows CEX and AEX chromatograms of a Fab (mAb fragment) reference sample 
and thermally stressed sample. In this case, the Fab molecule has a nominal pI value for the 
main species of 7.6. It should be noted that the separations on the AEX and CEX columns 
were each optimized independently for column type, pH value and salt gradient. It should 
also be noted that the terms “strong” and “weak” (in SAX, strong anion exchange, and 
WCX, weak cation exchange) refer to the extent of variation of ionization with pH due to the 
functional groups on the resin and not the strength of binding. Strong ion exchangers are 
completely ionized over a wide pH range whereas with weak ion exchangers, the degree of 
dissociation and thus exchange capacity varies much more markedly with pH.  For this 
example, SAX results in significantly more peaks and much better resolution of the charge 
species in comparison to the WCX chromatogram. Particularly interesting is that the 
difference between the WCX and SAX elution profiles are much more vivid for the stressed 
samples than for the reference materials. We have seen examples where the converse is true 
and the CEX separation is better than that observed on the AEX. This contrast between the 
AEX and CEX profiles highlights an important feature of IEC that electrophoretic methods 
don’t exhibit, which is the ability to magnify particular aspects of the protein structure and 
accentuate the separation of species relating to particular motifs (Vlasak & Ionescu, 2008).  
www.intechopen.com
Monoclonal Antibody Development and Physicochemical  
Characterization by High Performance Ion Exchange Chromatography 
 
449 
 
Fig. 6. Separation of Fab charge species using a weak cation exchange column (WCX) and a 
strong anion exchange column (SAX). Thermally stressed samples are labeled by incubation 
time and temperature of incubation. 
In general, we have observed that for the separation of mAb variants using ion-exchange 
chromatography, the optimized chromatogram has a relatively shallow gradient over a 
narrow range of salt concentration. A typical method results in 100 mM NaCl as the center 
point of the gradient, with salt concentration increasing over 70 mM NaCl in a linear 
gradient. It is recommended to perform iterative gradient optimizations to narrow the NaCl 
gradient down to around 2 mM/mL min-1. Iterative cycles are quicker and more predictive 
than performing a very long shallow gradient. 
Chromatograms obtained during the mobile phase pH value optimization for a mAb with a 
pI value around 9.5 are shown in Figure 7. Buffer species and buffer concentration for salt-
gradient IEC are generally not significant factors, but should be chosen considering target 
pH and buffer pKa.  
Although temperature does not significantly affect electrostatic interactions, it often affects 
the pH value of the mobile phase. This is particularly of concern for a Good’s buffer system 
(group of buffers described in the research of Dr. Norman Good et al. in 1966, often used for 
IEC and other biochemistry applications) (Good et al., 1966), which can exhibit a change in 
pH value of around 0.02 per °C temperature change. This sensitivity creates a need to 
control the column temperature carefully. A column compartment is always used, typically 
set at a value greater than 30°C to ensure good temperature stability in compartments that 
can only apply heat. Above 30°C, temperature control within +/- 1°C is readily achievable 
with commercially available equipment. 
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Fig. 7. Effect of mobile phase pH on mAb separation by WCX. The elution buffer (0.5 M 
NaCl) was increased linearly at 1 mM min-1 at a flow rate of 1 mL min-1 on a ProPac WCX-10 
column (4 x 250 mm), which was held at 30 ºC. Different initial salt concentrations were 
optimized for each pH value. Integration is shown, and main peak, acidic and basic regions 
are denoted. 
Subtle variations in selectivity with temperature may result from temperature-induced 
changes in mobile phase pH value (Figure 8). In Figure 8, the elution profile changes in two 
distinct regions as a function of temperature. Below 40°C, subtle changes in elution profile 
and retention times are observed consistent with minor changes to the mobile phase pH 
value as a function of temperature. However, above 40°C, the profiles exhibit much more 
radical changes with increasing temperature. This is interpreted to be related to the mAb 
having lost higher order structure at those elevated temperatures due to protein denaturing. 
For the mAb in Figure 8, it is clear that moderately elevated temperatures are not possible 
while maintaining the higher order structure; in general for IgG1 mAbs, chromatography at 
temperatures up to 55°C is readily possible. In summary, while mobile phase temperature 
does not affect protein charge directly, temperature can affect mobile phase pH and the 
structure of the protein, which can affect chromatographic separations. Thus, column 
temperature should be optimized considering these temperature effects.  
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Fig. 8. Effect of temperature on mAb separation by CEX. The elution buffer (0.2 M sodium 
sulfate) was increased linearly on a ProPacWCX-10 column (4 x 250 mm).  
8. Developing a pH gradient-based IEC method 
Despite good resolving power and robustness, salt-based ion exchange separations are 
usually protein-specific and time-consuming to develop. A novel pH-based separation of 
proteins by cation exchange chromatography that was multi-product, high-resolution, and 
robust against variations in sample matrix salt concentration and pH was recently reported 
(Farnan & Moreno, 2009). A pH gradient-based separation method using cation exchange 
chromatography was also evaluated in a mock validation and deemed highly robust (Rea et 
al., 2011). Figure 9 depicts the separation of 16 mAbs by pH gradient IEC (pH-IEC). Each 
mAb was injected sequentially, demonstrating that in contrast to salt-based IEC, pH-IEC can 
be used to analyze multiple mAbs with a single method. 
 
Fig. 9. Separation of 16 mAbs using a ProPac WCX-10 column by pH gradient IEC. Each 
mAb was analyzed using the same pH-IEC method, and each mAb was injected 
sequentially. mAb pI values ranged from pI 7.3 to pI 9.4. 
Similar to salt-gradient IEC methods, pH-IEC separations are developed by choosing a cation or 
anion exchanging column and varying the buffer system, pH of the mobile phases, and other 
operating parameters, such as temperature and flow rate. Figure 5 shows a typical development 
workflow for pH-IEC, and can serve as a guide for initial pH-IEC method development.  
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8.1 Column selection, buffers and operating parameters for pH gradient IEC 
Like conventional IEC, the conditions chosen for pH-IEC separations, such as buffer, pH, 
column temperature, and sample load, are dependent on the type of column selected. To 
choose a column, the pI of the mAb and the expected charge species should be considered. 
Considerations for column selection may differ slightly for pH-IEC compared to conventional 
IEC. For example, because the column will be exposed to a pH gradient, the column must be 
able to perform adequately over a large pH range, i.e., the charged groups on the 
chromatography resin must maintain their charge over the operating pH range. Also, buffer 
strength can affect resolution, and pH-IEC mobile phases typically have lower buffer strengths 
than conventional salt-gradient IEC. Several pH-IEC buffer systems have been published for 
mAb separations; these buffer systems can be used as starting points for formulating buffers 
for pH-IEC methods (Farnan and Moreno, 2009; Rea et al., 2011; Rozhkova, 2009). 
8.2 High-throughput multi-product separations using pH-IEC 
To increase the throughput of the analytical methods, smaller particle sizes and shorter 
column lengths are being utilized to reduce run time. In Figure 10, the utilization of a 3 µm 
particle size column reduced analysis time 16-fold compared to a 10 µm particle size 
column. Analysis times are greatly reduced using smaller particle sizes because as the 
particle size decreases, there a significant gain in column efficiency, and the efficiency does 
not decrease at increased flow rates or linear velocities (Swartz, 2005). In addition, because 
different mAbs can be analyzed using the same pH-IEC method in the same sequence, these 
high-throughput methods are capable of analyzing hundreds of mAbs per day, which is not 
possible with conventional, product-specific salt-based IEC.  
 
Fig. 10. Separation of a mAb using (A) a WCX column, 10 µm and (B) a SCX column, 3 µm, 
by pH gradient IEC. Each mAb was analyzed using the same buffers and gradient volume.  
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9. Hybrid/combination modes of IEC 
Salt and pH may be combined to elute proteins from IEC columns. Combination or hybrid 
methods can be employed if either salt-based or pH-based methods prove inadequate for 
resolving species of interest, especially at extreme pHs. When pH increases above their pKa, 
amines, as used exclusively in the pH-IEC piperazine/imidazole/tris buffer system, become 
deprotonated and uncharged, resulting in decreased ionic strength. The bound proteins will 
also deprotonate and carry less charge. However, adequate amounts of positively charged 
ions are required to displace the bound proteins and to elute them off the cation exchange 
resin. Since the buffer salts alone can not provide enough positively charged ions at higher 
pH, additional salt is added to the pH-IEC elution buffers to maintain ionic strength. Figure 
11 depicts measured conductivity as a function of elution time in pH-IEC with and without 
salt. In this case, adding salt to the elution buffer will compensate for the loss of ionic 
strength (represented by conductivity) due to deprotonation of buffer ions.  
In Figure 12, separation of the charge species of three mAbs using pH-IEC with and without 
salt is compared. Without salt, mAb-1 with a pI of 9.4 did not elute, and mAb-3, with a low 
pI of 6.2, showed a very broad peak with significant tailing and no resolution of charge 
species. With the addition of salt, adequate separation of charge species is obtained for both 
high pI and low pI mAbs.  
 
Fig. 11. Measured conductivity as a function of elution time in pH-IEC A) without, and B) 
with salt. Buffers are A) 11.6 mM piperazine, 1.5 mM imidazole, 2.4 mM Tris, B) 4 mM 
piperazine, 4 mM imidazole, 4 mM Tris, 16 mM NaCl. 
10. Equipment configurations to accelerate development 
Ionic strength gradient ion-exchange methods are typically product-specific, with each 
method requiring a unique pair of mobile phases and experimental conditions. As discussed 
above, a significant number of mobile phase pH values and gradient profiles need to be 
evaluated. Changing mobile phase pH values normally requires user intervention to supply 
new mobile phase pairs; the time needed to manually change the system can slow down 
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development. In order to more efficiently develop analytical IEC methods, alternative 
equipment configurations have been utilized to accelerate the selection of operational 
parameters, including quaternary buffer systems and customized solvent selection valves on 
the pump inlets to allow selection from an array of available solvents. Such modifications to 
the equipment and workflows can allow consecutive performance of significantly more 
experiments without requiring user intervention. 
0
20
40
60
80
100
120
140
0 10 20 30 40 50
Ab
so
rb
an
ce
 (m
Au
)
Time (min)
mAb-3 pI 6.2
mAb-2 pI 8.2
mAb-1 pI 9.4
blank
Piperazine 11.6 mM
Imidazole: 1.5 mM
Tris: 2.4 mM
0
20
40
60
80
100
120
140
0 10 20 30 40 50 60
Ab
so
rb
an
ce
 
(m
Au
)
Time (min)
blank
Piperazine 4 mM
Imidazole: 4 mM
Tris: 4 mM
16mM NaCl in Buffer B
mAb-3 pI 6.2
mAb-2 pI 8.2
mAb-1 pI 9.4
A: without salt
B: with salt
Ab
so
rb
an
ce
 (m
Au
)
Ab
so
rb
an
ce
 
(m
Au
)
 
Fig. 12. Separation of the charge species of three mAbs using pH gradient with and without 
salt in a ProPac WCX-10 column. A) pH 5 to 9.5 in 45 minutes, gradient 0.1 pH unit/min;  B) 
pH 5 - 10.8 in 58 minutes, gradient 0.1 pH unit/min. 
A quaternary buffer system can be utilized to develop a method and reduce the amount of 
user intervention by using a pair of buffer solvents (solvent lines A and B) to allow the pump 
to admix to achieve the desired mobile phase pH, and using two other solvents (solvent lines 
C and D) to generate the ionic strength gradient for elution. The quaternary system can apply 
different combinations of salt and pH by automatically programming the percentages of the 
four solvents to be mixed and applied to the column. Thus, programs can be generated to 
screen a variety of salt and pH conditions in a single sequence using only four buffers.  
Another approach, which is particularly important for binary pump systems, is to add a 
multi-port solvent selection valve to the system prior to the pump. Although the customized 
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valve system requires the production of many buffers, the multiple valve configurations can 
allow users to further customize buffer components and concentrations (as opposed to only 
salt gradient and pH) compared to the quaternary system. Such a system allows up to a 
dozen more buffer combinations to be evaluated without intervention.  
Because pH-IEC is performed by using a pH gradient and not a salt gradient, simply 
reversing the pH gradient allows for the chromatography mode to be switched between  
CEX and AEX. This reversal of gradient can be automatically performed through the 
chromatography software. Thus, multiple CEX and AEX columns can be screened by using 
only two buffers at different pH’s and using a column switching valve to screen different 
column types (Figure 13). During development, it is helpful to have online pH and 
conductivity meters to ensure that the pH gradient is roughly linear and that the 
conductivity does not interfere with the separation efficiency. 
 
Fig. 13. HPLC column compartment equipped with a 6-port column switching valve, for 
screening of up to six different columns for pH-IEC without the need to change buffers or 
columns. 
11. Method robustness and validation 
The robustness of an analytical procedure is a measure of its capability to remain unaffected 
by small, but deliberate variations in method parameters and provides an indication of its 
reliability during normal usage. For IEC, robustness can be evaluated by varying parameters 
such as injection volume, buffer pH, flow rate, and column temperature. In addition to 
robustness, intermediate precision can be demonstrated by evaluating inter-laboratory 
variations, such as different days of analysis and different analysts. Furthermore, the ability 
to use different instrument and column manufacturers for a particular method greatly 
reduces the business risk of the method; if a column supplier cannot meet demand or if an 
instrument manufacturer ceases production of a particular instrument model, method 
transfer to other instruments and columns can occur without loss of performance.  
11.1 Obtaining robust performance 
Obtaining robust performance of an IEC method often goes beyond the design of the 
method itself, and involves good equipment hygiene, elimination of metal corrosion (e.g. 
formation of iron oxide) and contamination (e.g. presence of metal ions such as Fe3+ ions), 
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and mitigates the differences between instrument types. Problematic metal contamination 
typically results from corrosion of the fluid-contacting metal parts and can be avoided by 
using PEEK or titanium materials in the fluid paths. Good practices on obtaining robust 
method performance are discussed in the following sections. 
11.1.1 Equipment hygiene 
Maintaining good equipment hygiene is important in order to achieve robust performance. 
The following are good practices to ensure instrument hygiene:  
1. Filter mobile phases that are amenable to microbial growth with 0.2 mm filters prior to 
use; replace solvent reservoir filters (sinkers) each time mobile phase bottles are 
replenished; 
2. Flush and store HPLC system in 10% isopropanol in water when not in use, to prevent 
growth of microbes;  
3. Leave the system running at low flow rates to prevent salt build up and clogging;  
4. Keep all lines flushing as opposed to just a single channel;  
5. Flush auto-sampler components as needed with 10% isopropanol in water;  
6. Follow manufacturer’s instructions regarding proper maintenance of HPLC 
instrumentation. 
11.1.2 Metal contamination 
Metals can negatively affect the ion-exchange chromatography of proteins. Protein chelation 
with metals are a secondary retention mechanism to the primary electrostatic interaction of 
ion-exchange chromatography. This secondary interaction results in peak tailing. These 
interactions can either occur with metal contaminating the column or with corroded 
surfaces within the HPLC. In addition to affecting separation, corrosion can result in 
physical damage to system, such pump seal failure and compromised performance of the 
detector cells. Halide containing eluents readily corrode HPLC systems manufactured from 
stainless steel, as stainless steel has the propensity to form rust (Collins et al., 2000a). 
Sodium acetate or sodium sulfate can be used as an eluting salt instead of halides; however, 
sulfate is divalent, thus concentrations in the eluting mobile phase would be different 
compared to using a halide, as halides are monovalent.  
Metal contamination may be reversed by flushing with chelating agents such as oxalic acid 
dihydrate (Rao & Pohl, 2011). Also, stainless steel systems may require periodic passivation 
for reliable usage (Collins et al., 2000b). In light of the drawbacks of using a stainless steel 
HPLC system, more manufacturers are including biocompatible equipment (e.g. Titanium 
or PEEK) for analyzing mAbs and other protein products.  
11.1.3 Transferring methods between instrument types 
Transferring methods between instruments from different manufacturers can pose 
challenges due to the differences between instruments. As mentioned previously, 
equipment composition (e.g. stainless steel vs. titanium) is one of the factors to be 
considered when transferring a method between instrument types, in addition to gradient 
delay, mixing volumes, pump capabilities, and column compartment temperature ranges. 
Gradient delay and mixing volumes can differ between instruments, but they are generally 
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only a significant concern for very fast gradient separations. In addition, shallow IEC 
gradients can challenge the performance of an HPLC; however, most gradients are >70 mM 
salt and can be proportioned over 30-40% of the pump range, well within the capabilities of 
modern pumps. Often a gradient hold for 5 minutes at the initial salt concentration is 
included, just in case a method is particularly sensitive when being transferred from one 
equipment type to another. In such cases the hold time can be adjusted to compensate for 
differences in the gradient delay volume between the instruments. 
Temperatures inside the column are dependent on oven design and plumbing 
configuration. Having a pre-column heat exchanger in line or out of line could make a 
several degree difference in the temperature at which the column chemistry occurs. This is 
particularly concerning for buffers with which the pH can change rapidly with temperature. 
Figure 14 shows a comparison of column compartment temperature settings for two 
different instruments from different manufacturers. To make the correlation, thermocouples 
were fitted into T-pieces in the fluid path inside the column oven, but just prior to the 
column, and temperatures were measured for a range of column compartment set points 
and mobile phase flow rates. These measurements were used to estimate the temperature of 
mobile phase going through the column for each set point. By equating the measured fluid 
temperatures for each flow rate, the correlation of column compartment temperatures were 
plotted. It is noted in this correlation that there was also a significant effect of the mobile 
phase flow rate on the correlation. 
Different detectors can sometimes yield differences in baseline slope. This can occur when 
moving from a single/double wavelength detector with a reference beam to a photodiode 
array (PDA) detector. The selection of an appropriate reference wavelength and bandwidth 
on the PDA can overcome detector variance. 
 
Fig. 14. Comparison of column compartment temperature settings required to achieve the 
same columns compartment temperature for two different HPLC models at different flow 
rates. Results are shown for a 4 x 250 mm Dionex ProPac column. The Agilent 1100 HPLC 
was configured using only the left hand side heat exchanger. The Waters 2695 HPLC was 
configured with the solvent pre-heater in-line. 
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11.2 Method validation 
Before an analytical method can be incorporated into a characterization platform or a quality 
control system, it must first be demonstrated that the method is suitable for its intended 
purpose. Guidelines for validation of analytical methods have been published in the United 
States Pharmacopeia, by the International Conference on Harmonization (ICH), US Food 
and Drug Administration (FDA), and in published reviews (Bakshi & Singh, 2002). Methods 
must be evaluated considering regulatory requirements and validation procedures. In other 
words, the “validatability” of these methods must be assessed before implementation. 
Validation tests include precision, accuracy, and linearity. Intermediate precision is tested 
by using multiple instruments, multiple analysts, and multiple column lots. Methods must 
be validated and documented according to regulatory requirements prior to implementation 
into a control system for lot release of drug substance and drug product. Robustness studies 
can also be performed in conjunction with method validation. It has been our experience 
that the most significant effects on method robustness are: mobile phase pH value, column 
temperature, metal contamination and column age. 
A system suitability range can be obtained from robustness studies. This range is often 
based on the standard deviation of the mean for a particular measured component, such as 
main peak relative area. The system suitability range indicates the precision of the method. 
pH-IEC may demonstrate an improvement in precision over conventional salt-based IEC 
(Rea et al., 2011). The 6σ ranges in Figure 15, which predicts a 99% method success rate, 
demonstrate the improved precision of the pH-gradient IEC method over conventional IEC, 
which can have a 6σ range of up to 8% main peak relative area (Figure 15).  
 
Fig. 15. Six sigma range (±3SD) for main peak relative area for salt gradient IEC (diamonds) 
and pH gradient IEC (circles) for a variety of mAbs. 
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12. Automation in sample preparation and data handling 
In addition to high-throughput and multi-product analytical methods, the use of robotics 
for sample preparation automation may further reduce sample analysis time and cost. 
There are several companies that provide liquid handling automation instruments, 
including LEAP Technologies and TECAN. The LEAP Technologies CTC PAL liquid 
handling system is capable of on-the-fly sample preparation, such as protein dilution and 
digestion. On-the-fly sample preparations are viable if the sample preparation takes less 
time than the analytical method. For sample preparations that take longer than the 
analytical run time, batch sample preparation can be performed using robotic liquid 
handling systems such as the TECAN Freedom EVO, which can handle multi-well plates 
for increased sample throughput. Robotic liquid samplers can increase reproducibility, 
efficiency and safety compared to manual handling of samples.  
The final steps to most characterization workflows include data analysis and report 
generation. Several software packages are available that are designed to reduce the time 
necessary to complete post-data acquisition tasks. For liquid chromatography applications, 
commercially available chromatography data software, such as Dionex’s Chromeleon 
Chromatography Management Software and Waters Corporation’s Empower 
Chromatography Data Software, include features such as automated peak integration and 
one-click report generation. In addition, laboratories are increasingly implementing 
electronic laboratory notebooks, which has advantages over traditional laboratory 
notebooks, including ease of data sharing and collaboration, streamlined review and 
witnessing processes, standardized documentation, and long-term data preservation. 
13. Conclusion  
Monoclonal antibodies are valuable therapeutic products that are approved for a variety of 
indications. In this chapter, mAb development, production, purification, formulation, 
characterization and regulatory requirements were discussed, followed by a more detailed 
discussion on charge species analysis using IEC. Method development strategies, method 
robustness, validation and automation, as well as applications of salt-gradient and pH-
gradient IEC methodologies for the analysis of mAbs were also covered. This chapter is 
intended to be a reference text for scientists such that a concise strategy can be implemented 
for developing robust IEC methods for the characterization of therapeutic mAbs, resulting 
in shorter method development times and enabling faster analysis of mAb products to 
support biopharmaceutical pipelines. 
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